Silo Pharma, Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a critical inflection point, attempting to bridge the gap between a speculative research project and a viable commercial entity. The successful consolidation of IP from Columbia University and the validation from Aikido Pharma provide a legitimate scientific foundation, but these are currently overshadowed by a fragile balance sheet and a looming Nasdaq compliance deadline. The investment thesis now hinges on a binary outcome: whether the company can hit its 2026 IND target for SPC-15 before its cash reserves dwindle or the market forces a dilutive capital raise. While the buyback program and crypto treasury are designed to attract a different class of investor, the fundamental risk remains the high cost of drug development and the volatility of a micro-cap stock trading near the delisting threshold.